Navigation Links
Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
Date:11/19/2008

KVISTGARD, Denmark, November 19 /PRNewswire-FirstCall/ -- Bavarian Nordic has invoiced the U.S. authorities for another milestone payment of USD 25 million as allowed under the RFP-3 contract to manufacture and deliver 20 million doses of the company's IMVAMUNE(R) smallpox vaccine. This milestone payment was triggered by the recent submission of a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects, which is part of the regulatory package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency. With this, Bavarian Nordic is an important step closer to fulfilling the conditions for initiating delivery of IMVAMUNE(R) in 2009.

The income will be recognised as revenue in the financial statements for 2008.

With this payment, Bavarian Nordic has so far invoiced a total of USD 125 million in advance- and milestone payments under the RFP-3 contract, of which USD 50 million has not yet been recognised in the income statement.

This announcement does not change Bavarian Nordic's previously announced financial guidance for 2008.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "Since the award of the RFP-3 we have successfully met all agreed objectives in the contract with the U.S. Department of Health and Human Services and we find this very satisfactory. The submission of these clinical data concludes the data package that may support the use of IMVAMUNE(R) in a declared emergency and marks an important event for the company this year. This submission is part of the company's plan to support the delivery of IMVAMUNE(R) which is planned to start during 2009".

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The c
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
4. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
5. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
6. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
7. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
8. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
9. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
10. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
11. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2009)... A new statistical analysis technique that identif...nt-based artifacts from experimental data could le...omaterials and nanostructures likely to have futur... profile adjustment by regression (SPAR), the tech... data required to make conclusions, and help disti...
(Date:7/1/2009)... LONDON, July 1 Johnson & ...director of the Department of Molecular Biology at...ny, whose discoveries have led to novel cancer the...he winner of the 2009 Dr. Paul Janssen Award for B...rld-renowned scientists selected Dr. Ullrich, who ...
(Date:7/1/2009)... VYVANSE is the first stimulant to establish durat...r administration in adults with ADHD , , HOLLYW...plc (LSE: SHP, Nasdaq: SHPGY ), the global speci...sults from a Phase 3b study that found VYVANSE(R) ...nificant efficacy at 14 hours after administration...
(Date:7/1/2009)... NEW YORK, July 1 NeoSte...t has raised additional gross funds of over $4 mil...se funds, together with the $11 million private pl...April 13, 2009, bring the total investment obtaine...er $15 million. In addition, affiliates of Suzhou...
Breaking Biology Technology:New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 2Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 3Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 4Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 6Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 7Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 8NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 2NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 3
...ollaborative software tools offer many ways to sha...mail. Now there may be a halfway point. , ,We all ...y portals, even customer service chat portals. Som... management, document management all these are no...ut fee-based Web based applications that are avai...
...ADISON, Wis-- Sonic Foundry, Inc. , a rich media s...fiscal 2003 year ended Sept. 30, 2003. During fisc...ion of its business, selling off both its Media Se...lusively on the rich media Web communications mark...ong ramp up in sales in line with early stage busi...
...ondays Wall Street Journal featured the news of ...ech company Esperion Therapeutics for $1.3 billi...h., develops cardiovascular medicine that may be u...osclerosis. Remember that Pfizer has a huge cardio...h cholesterol ($8 billion in annual sales) and Nor...
...ADISON, WI - To survive and thrive in a decidedly ...mical trick to evade the propulsive nature of its ...chemistry, scientists at the University of Wiscons...ow the transit of drugs through the intestine, mak...ing out the promise not only of more effective tre...
Other Biology Technology:E-Mail Collaboration Problems 2E-Mail Collaboration Problems 3E-Mail Collaboration Problems 4Sonic Foundry Reports Fiscal 2003 Results 2Holiday Gift From Big Pharma 2Tapeworm's Chemical Trick Could Make Drugs More Effective 2
(Date:7/2/2009)... , Researchers from the National Oceanography Cen...orth of oceanographic knowledge to investigate the...ing crab. The results, published this week in the...a driving force behind the speciation and radiatio... tens of millions of years of Earth,s history. ,...
(Date:7/2/2009)... , Keri Smith, Ph.D., an assistant professor of p... of Texas Health Science Center at Houston, has re...l Hemophilia Foundation. , The award will suppo...apy for people with Hemophilia A, a bleeding disor...nt. Hemophilia A affects about one in every 5,000 ...
(Date:7/2/2009)... , Scientists have performed the first DNA-based ...g prehistoric feathers recovered from caves and ro...he University of Adelaide and Landcare Research in...ecies after retrieving ancient DNA from moa feathe... giant birds measuring up to 2.5 metres and weigh...
(Date:7/1/2009)... , The University of Manchester and the European ...tics Institute (EMBL-EBI) have launched a major ne...ccelerate research into treatments for H1N1 flu an...gistry of curated life science Web Services, is be...t the 17th Annual International Conference on Inte...
Breaking Biology News(10 mins):Evolution: Crabs go deep to avoid hot water 2UT scientist receives hemophilia research award 2Scientists 'rebuild' giant moa using ancient DNA 2New e-science service could accelerate cancer research 2New Resource for Taking Care of Aging Parents Available in Beta 1715 1New Resource for Taking Care of Aging Parents Available in Beta 1715 2New Resource for Taking Care of Aging Parents Available in Beta 1715 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 726 1Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 726 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 726 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 726 4Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 1Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 2Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 3Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 4Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 5Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 6Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 7Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 8Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 9Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 10Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 11Lilly Files for European Approval of ALIMTA 28R 29 28pemetrexed for injection 29 for First Line Treatment of Non Small Cell Lung Cancer 346 12NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 341 1NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 341 2NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 341 3NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 341 4
...paradigm, Luiz Rocha and colleagues from the Smith...sity the University of Florida and the University ... habitats may differ more from one another than fr...ciation model for coral reef organisms may spur th...ciation on land and sea. , Coral reefs, like tropi...
...on,t heal like young ones. But it turns out that,s...sue of Nature shows that it,s old blood that keeps...do, MD, PhD, associate professor of neurology and ...chool of Medicine, built on previous work showing ...elves but fail to do so. Rando and his group studi...
...ole in the spread of disease and in the formation ...cal theories about nanobacteria ?micro-organisms c...ouds are published in two recent articles in the J... of the University of Ulm, Germany, and Professor ..., They say nanobacteria are now accepted as being...
...etected the largest "gene deserts" known in the hu...chromosome 2 arose from the fusion of two ancestra...tional Human Genome Research Institute (NHGRI), pa...orted today. , In a study published in the April 7...team, led by Washington University School of Medic...
Other Biology News:An (ecological) origin of species for tropical reef fish 2Young Blood Revives Aging Muscles, Stanford Researchers Find 2Young Blood Revives Aging Muscles, Stanford Researchers Find 3Nanobacteria in clouds could spread disease, scientists claim 2Scientists analyze chromosomes 2 and 4 2Scientists analyze chromosomes 2 and 4 3
...tion, spotting and preparation for MS analysis. Wi...y and continuously spotted onto target plates, in ...on of target plates for MALDI-TOF-MS measurements....sional Micro LC System and Shimadzu Biotechs AXIMA...
...o-dimensional fractionation system for high-resolu...f Beckman Coulters ProteomeLab family of products,...stem effectively resolves the thousands of protein...nge in todays proteomics research.In the first dim...
... designed for full-length gene cloning and require...DNA clone. The first PCR analysis is performed in ... plasmid DNA from 5,000 clones. Having identified ... reaction products, the second PCR analysis is car...
...kinase profiling, quantitative measurement of kina... built on the flexible and powerful Paraflo microf...ys are available as part of our comprehensive Prot... Probe Content Our standard content PKS peptid...
Biology Products: